Metabolome analysis of erythrocytes from patients with chronic hepatitis C reveals the etiology of ribavirin-induced hemolysis

International Journal of Medical Sciences

Volumn 10, Issue 11, 2013, Pages 1575-1577

  Karasawa, Tetsuru ^a   Saito, Takafumi ^a   Ueno, Yoshiyuki ^a   Sugimoto, Masahiro ^b   Soga, Tomoyoshi ^b  

^a YAMAGATA UNIVERSITY   (Japan)

^b KEIO UNIVERSITY   (Japan)

Author keywords

Anemia; Glycolysis; HCV; Metabolome; Pentose phosphate cycle; Ribavirin

Indexed keywords

2,3 DIPHOSPHOGLYCERIC ACID; 3 PHOSPHOGLYCERIC ACID; ADENOSINE TRIPHOSPHATE; FRUCTOSE 6 PHOSPHATE; GLUCOSE 6 PHOSPHATE; HYDROXYACID; PEGINTERFERON; RIBAVIRIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CAPILLARY ELECTROPHORESIS; CLINICAL ARTICLE; ENERGY METABOLISM; ERYTHROCYTE; ERYTHROCYTE COUNT; ERYTHROCYTE METABOLISM; FEMALE; GLYCOLYSIS; HEMOLYSIS; HEPATITIS C; HUMAN; HUMAN CELL; MALE; METABOLOMICS; OXIDATIVE STRESS; PENTOSE PHOSPHATE CYCLE; SIDE EFFECT; TIME OF FLIGHT MASS SPECTROMETRY; TREATMENT DURATION;

ANEMIA; GLYCOLYSIS; HCV; METABOLOME; PENTOSE PHOSPHATE CYCLE.; RIBAVIRIN;

ANTIVIRAL AGENTS; ERYTHROCYTES; GLYCOLYSIS; HEMOLYSIS; HEPATITIS C, CHRONIC; HUMANS; OXIDATIVE STRESS; PENTOSE PHOSPHATE PATHWAY; RIBAVIRIN;

EID: 84883862332     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.6436     Document Type: Article

References (12)

1. Hynicka LM, Heil EL. Anemia management in patients with chronic viral hepatitis C. Ann Pharmacother. 2013;47:228-236.
2. Jacobson IM, Kowdley KV, Kwo PY. Anemia management in the era of triple combination therapy for chronic HCV. Gastroenterol Hepatol (N Y).2012; 8 (9 Suppl 6):1-16.
3. Grattagliano I, Russmann S, Palmieri VO, et al. Glutathione peroxidase, thioredoxin, and membrane protein changes in erythrocytes predict ribavirin-induced anemia. Clin Pharmacol Ther 2005; 78: 422-432.
4. De Franceschi L, Fattovich G, Turrini F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: Role of membrane oxidative damage. Hepatology 2000; 31: 997-1004.
5. Page T, Connor JD. The metabolism of ribavirin in erythrocytes and nucleated cells. Int J Biochem 1990;22:379-383.
6. Editors of the Drafting Committee for Hepatitis Management Guidelines: The Japan Society of Hepatology. Guidelines for the Management of Hepatitis C Virus Infection. First edition, May 2012, The Japan Society of Hepatology. Hepatol Res 2013; 43: 1-34.
7. Soga T, Baran R, Suematsu M, et al. Differential metabolomics reveals ophthalmic acid as an oxidative stress biomarker indicating hepatic glutathione consumption. J Biol Chem 2006;281:16768-76.
8. Shintani T, Iwabuchi T, Soga T, et al. Cystathionine beta-synthase as a carbon monoxide-sensitive regulator of bile excretion. Hepatology 2009;49:141-50.
9. Soga T, Sugimoto M, Honma M, et al. Serum metabolomics reveals γ-glutamyl dipeptides as biomarkers for discrimination among different forms of liver disease. J Hepatol 2011;55:896-905
10. Lau JY, Tam RC, Liang TJ, et al. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 2002; 35: 1002-1008.
11. Hitomi Y, Cirulli ET, Fellay J, et al. Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function. Gastroenterology 2011; 140:1314-1321.
12. Fellay J, Thompson AJ, Ge D, et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 2010; 464: 405-408.